Cystoseira canariensis

Identity: Taxonomy, Nomenclature, and Natural Source

Botanical Classification

Cystoseira canariensis is a species of marine brown macroalga. The genus Cystoseira (family Sargassaceae) is composed of approximately 40 species distributed along the Eastern Atlantic and Mediterranean coasts. Cystoseira canariensis was formally described by Sauvageau in 1912, with the lectotype locality recorded as Puerto de la Cruz (formerly Puerto Orotava) in Tenerife, Canary Islands, Spain. The species epithet canariensis is a Latin adjective meaning "living in or from the Canary Islands."

The full accepted classification places the organism within Kingdom Chromista (or Stramenopiles), Division Ochrophyta, Class Phaeophyceae, Order Fucales, Family Sargassaceae, Genus Cystoseira. According to AlgaeBase, the name Cystoseira canariensis Sauvageau is currently regarded as a synonym of Cystoseira humilis Schousboe ex Kützing. This synonymy reflects ongoing taxonomic revision within the group.

Taxonomic Complexity and Reclassification

The genus Cystoseira is widely distributed throughout the Atlantic and Mediterranean regions; however, taxonomic classification within the genus is challenging and controversial, in part because erroneous taxonomic assignments are frequent due to the wide morphological variability of Cystoseira individuals, and because many species are still undergoing active speciation and hybridization. Phylogenetic analysis has identified the polyphyletic nature of the genus. In response to this complexity, Molinari and Guiry (2020) re-instated the genera Gongolaria Boehmer and Ericaria Stackhouse for several formerly recognized Cystoseira clades, due to the principle of taxonomic priority. In the Mediterranean Sea, Cystoseira sensu lato now encompasses the genera Cystoseira sensu stricto, Ericaria, and Gongolaria. The name Cystoseira canariensis persists in the dietary supplement literature and in earlier scientific papers, though researchers and consumers should be aware of this evolving nomenclature.

Distribution and Natural Habitat

Cystoseira canariensis is a species of brown seaweed native to the eastern Atlantic, particularly the Canary Islands. The importance of the genus Cystoseira is underscored by the observation that its members produce several potentially bioactive metabolites; the genus is common and widely distributed throughout the Atlantic and Mediterranean regions. Members of the genus occupy shallow coastal rocky shores and subtidal zones, forming kelp-like canopy structures that serve as ecologically important foundation species.

Commercial Forms and Preparations

As a dietary supplement ingredient, Cystoseira canariensis has been sold predominantly as a dried whole-thallus powder or as a standardized extract of its sulfated polysaccharide (SP) fraction. The proprietary extract derived from this species was commercially marketed under product names such as "CSP-3" and incorporated into branded supplements including "Myostat" and "MyoBlast." CSP-3 was described as an array of sulfated polysaccharides extracted from Cystoseira canariensis. A common therapeutic dosage cited for Cystoseira canariensis is approximately 1,200 milligrams per day, typically divided into three doses.

---

Traditional and Historical Use

Cystoseira canariensis itself does not appear in historical pharmacopeias, classical herbals, or well-documented traditional medicine monographs from specific named traditions. The species occurs in a geographically restricted zone centered on the Canary Islands, and no peer-reviewed ethnopharmacological records specifically document its use in named traditional medical systems with verifiable historical depth.

Traditionally, seaweeds from the Cystoseira genus have been utilized in folk diets and remedies, valued for their rich content of bioactive compounds such as polysaccharides, polyphenols, vitamins, and minerals. Within the broader context of Atlantic and Macaronesian coastal communities, brown seaweeds in general were gathered for use as food, as soil fertilizers, and as components of folk preparations. However, documented traditional use specific to C. canariensis as a distinct species—as opposed to Macaronesian seaweeds in general—is not substantiated in the peer-reviewed or institutional literature consulted for this article. Any such claims should be treated with caution in the absence of primary ethnographic sources.

---

Key Constituents and Active Compounds

Overview of the Cystoseira Chemical Profile

Chemically, the Cystoseira genus contains a wide variety of secondary metabolites, including terpenoids, steroids, phlorotannins, and phenolic compounds; additionally, other chemical components such as carbohydrates, triacylglycerols, fatty acids, pigments, and vitamins have been identified in studied species. Some of these isolated compounds have been associated with pharmacological properties including antioxidant, anti-inflammatory, cytotoxic, anticancer, cholinesterase inhibition, antidiabetic, antibacterial, antifungal, and antiparasitic activities.

Sulfated Polysaccharides (Fucoidans)

The most scientifically scrutinized class of compounds in C. canariensis is its sulfated polysaccharide (SP) fraction, often referred to as fucoidan-type material. Natural sulfated polysaccharides derived from brown seaweeds comprise a complex group of macromolecules with a wide range of important physiological properties; they have been shown to bind and directly regulate the bioactivity of growth factors and cytokines such as basic fibroblast growth factor, interferon, various enzymes, and transforming growth factor.

For related Cystoseira species, structural characterization has revealed that fucoidans in this genus tend to be sulfated heterogalactofucans or xylogalactofucans. The sulfate content of Cystoseira fucoidans is relatively low compared to other brown algal genera. The chemical composition of fucoidans is greatly influenced by the source, species, geographic location, and extraction process; the activity of sulfated polysaccharides depends not only on composition but also on molecular weight, molecular structure, and route of administration.

Meroterpenoids and Terpenoids

Terpenoids, phenols, carotenoids, tetraprenyltoluquinols, naphthoquinones, diterpenoids, and acetogenins have been found in Cystoseira and have been used in the chemotaxonomy of this genus. Meroditerpenoids — hybrid molecules derived from both terpenoid and polyketide biosynthetic pathways — are characteristic of the genus. These compounds, which include tetraprenyltoluquinol and tetraprenyltoluquinone derivatives, have been associated with antioxidant and anti-inflammatory properties in related species.

Sterols

Fucosterol is among the sterols reported in Cystoseira algae, analogously to other brown algae. Fucosterol is structurally related to cholesterol and is one of the predominant sterols of brown marine algae.

Phlorotannins and Other Polyphenols

Phytochemical studies have revealed that Cystoseira species are rich in phlorotannins, sterols, meroditerpenoids, and sesquiterpenoids, some of which exhibit antioxidant, antitumoral, antifouling, and antimicrobial activities. Phlorotannins are polymers of phloroglucinol (1,3,5-trihydroxybenzene) unique to brown seaweeds, with notable free-radical scavenging capacity.

---

Proposed Mechanisms of Action

Myostatin Binding (Sulfated Polysaccharide Mechanism)

The primary mechanism that drove commercial interest in C. canariensis was the proposed inhibition of myostatin via direct binding. Sulfated polysaccharides have been shown to bind and directly regulate the bioactivity of growth factors and cytokines; myostatin is a member of the transforming growth factor-beta (TGF-beta) family that acts as a negative regulator of skeletal muscle mass; and it was demonstrated that SPs isolated from Cystoseira canariensis bind to the myostatin protein in serum.

Myostatin is a member of the TGF-beta family that acts as a negative regulator of skeletal muscle mass. The theoretical basis for using C. canariensis was that if its SPs could bind serum myostatin in the same way as observed in vitro, the functional amount of active myostatin in circulation would be reduced, thereby releasing its inhibitory grip on muscle growth. Given that myostatin is a negative regulator of muscle growth, if the myostatin binding effect occurring in vitro were replicated in vivo, it was theorized that the SP fraction (CSP-3) could increase muscle-protein synthesis and muscle growth. This mechanism, however, was only demonstrated in an in vitro binding assay and was not confirmed in controlled human studies (see Scientific Evidence section).

Antioxidant Mechanisms

The phlorotannins and meroterpenoids found across the Cystoseira genus exert antioxidant effects primarily through free-radical scavenging. Studies on related species have demonstrated radical-scavenging activity in DPPH assays, and hydroquinone-type meroterpenoids have been identified as particularly potent antioxidants.

Anti-inflammatory Mechanisms

Fucoidans derived from algae have been the subject of much research regarding their multiple biological activities; several research studies focus on their various pharmacological effects, including antitumor, immunomodulatory, antiviral, antimicrobial, antidiabetic, nephroprotective, antioxidant, anti-inflammatory, and anticoagulant effects. Anti-inflammatory properties in related Cystoseira species have been attributed to downregulation of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6.

---

Scientific Evidence by Area of Use

1. Myostatin Inhibition and Skeletal Muscle Mass

In Vitro Binding Evidence (Ramazanov et al., 2003)

The foundational evidence for C. canariensis as a supplement came from a 2003 publication in Acta Physiologica et Pharmacologica Bulgarica. Natural sulfated polysaccharides derived from brown seaweed comprise a complex group of macromolecules with a wide range of important physiological properties; they have been shown to bind and directly regulate the bioactivity of growth factors and cytokines; myostatin is a member of the TGF-beta family that acts as a negative regulator of skeletal muscle mass; and the study demonstrated that SPs isolated from the brown seaweed Cystoseira canariensis bind to the myostatin protein in serum. This was fundamentally a biochemical binding assay rather than a clinical intervention study, and it did not measure outcomes in living subjects such as changes in muscle mass or strength.

The Willoughby (2004) Human Randomized Controlled Trial

The pivotal human trial testing C. canariensis supplementation was a randomized, double-blind, placebo-controlled study published by Darryn S. Willoughby in the International Journal of Sport Nutrition and Exercise Metabolism in 2004 (PMID: 15467103). The study examined 12 weeks of resistance training and Cystoseira canariensis supplementation on serum levels of myostatin and follistatin-like related gene (FLRG), as well as muscle strength and body composition; twenty-two untrained males were randomly assigned to a placebo group or a myostatin-binder group in a double-blind fashion; blood was obtained before and after 6 and 12 weeks of training.

Both groups trained three days per week using 3 sets of 6 to 8 repetitions at 85–90% of one-repetition maximum; the supplemented group ingested 1,200 mg/d of Cystoseira canariensis.

After training, total body mass, fat-free mass, muscle strength, thigh volume/mass, and serum myostatin and FLRG increased for both groups (P < 0.05); however, there were no differences between groups (P > 0.05). Twelve weeks of heavy resistance training and 1,200 mg/d of Cystoseira canariensis supplementation appeared ineffective at inhibiting serum myostatin and increasing muscle strength and mass or decreasing fat mass.

Willoughby (2004) was the first researcher to investigate the effects of a supplement on myostatin concentrations using a commercial supplement based on brown algae (Cystoseira canariensis); the researchers subjected 22 men with no previous strength training experience to 12 weeks of resistance training receiving 1,200 mg/d of brown seaweed or placebo, and serum myostatin concentrations increased equivalently between the groups.

Animal Study (Bertoncello et al., 2015)

The maximum load supported by the gastrocnemius muscle of female rats after the administering of Cystoseira canariensis, either associated or not with swimming, was evaluated; 28 young Wistar female rats were divided into 4 groups: control, supplement, supplement and swimming, and swimming; each animal in the supplement groups received 20 mg of myostatin inhibitor per day; the swimming protocol was aerobic, performed three times per week during eight weeks. This was a preclinical animal study; its results cannot be directly extrapolated to human supplementation efficacy.

Confirmation Studies and Summary of Evidence Strength

Despite the initial laboratory evidence, human models have not been as successful in increasing body mass and muscle mass; further research is needed to see if sulfo-polysaccharides or Cystoseira canariensis have any beneficial effect in humans in response to resistance training.

Study results showed no difference in outcome between the treatment and placebo groups; although a single study cannot prove lack of efficacy, this outcome clearly demonstrated that cystoseira had been brought to market prematurely; studies that followed only confirmed these results, showing that supplements like cystoseira did not decrease myostatin levels.

Overall evidence strength for this indication: Very weak. The sole positive evidence is an in vitro binding assay. The only published randomized controlled trial in humans found no significant benefit on any outcome measure. No subsequent human RCTs have reversed this conclusion.

2. Antioxidant Activity

Research on the antioxidant potential of Cystoseira genus members is principally derived from in vitro studies of related species, not from clinical trials specifically involving C. canariensis. These species have shown very high antioxidant activity; in the Mediterranean Sea, Cystoseira sensu lato holds very promising features in terms of secondary metabolite production; many interesting molecules such as terpenoids, alkaloids, and steroids have been isolated from different species of the genus, but few studies on the pharmacological properties of these compounds have been published.

Overall evidence strength for this indication: Preliminary and indirect. Existing antioxidant evidence is entirely in vitro and derived from related species rather than clinical studies of C. canariensis itself.

3. Anti-inflammatory Activity

Research into anti-inflammatory properties of Cystoseira fucoidans has been conducted in animal models using closely related species rather than C. canariensis directly. Studies on Cystoseira sedoides, C. compressa, and C. crinita have demonstrated that their isolated fucoidans can reduce paw edema in the carrageenan-induced rat model. Seaweed polysaccharides are highly active natural substances; one study characterized the physico-chemical properties of sulphated polysaccharides from three Mediterranean brown seaweeds (Cystoseira sedoides, Cystoseira compressa, and Cystoseira crinita) and evaluated their anti-radical, anti-inflammatory, and gastroprotective activities. Pharmacological evaluation of the isolated fucoidans from these three species established that they exhibited significant anti-inflammatory activity at a dose of 50 mg/kg (i.p.), with percentages of inhibition of oedema of 51%, 57%, and 58%, respectively.

For Ericaria crinita (formerly Cystoseira crinita), a closely related Atlantic and Mediterranean species, subchronic treatment with fucoidan attenuated inflammation during the late phase of carrageenan-induced paw edema, with peak activity at the third hour after application. A significant decrease in serum levels of IL-1β in rats treated with both doses of C. crinita fucoidan was observed in comparison to controls, whereas TNF-α concentrations were reduced in the group treated with fucoidan at the dose of 25 mg/kg body weight.

Overall evidence strength for this indication in C. canariensis: Indirect. No controlled studies specifically on C. canariensis for anti-inflammatory endpoints have been published in the peer-reviewed literature identified in this review. Available evidence is from related species in rodent models.

4. Antidiabetic Activity

Recent scientific studies have explored the antidiabetic potential of Cystoseira species, including C. canariensis, due to their rich content of bioactive compounds such as phlorotannins, fucoxanthin, and polysaccharides; in vitro and in vivo animal studies suggest that extracts from Cystoseira species can inhibit carbohydrate-hydrolyzing enzymes like α-amylase and α-glucosidase, which may help reduce postprandial blood glucose levels.

Overall evidence strength for this indication: Very preliminary. Only in vitro and animal data exist, with no human clinical evidence specifically for C. canariensis.

---

Body Systems and Health Areas of Association

• Skeletal muscle / musculoskeletal system: The primary area of research and commercial application. The proposed mechanism (myostatin inhibition via sulfated polysaccharide binding) has not been confirmed in human trials.
• Immune and inflammatory systems: Sulfated polysaccharides (fucoidans) from closely related species have demonstrated immunomodulatory and anti-inflammatory properties in preclinical models. SPs have been shown to bind and directly regulate the bioactivity of growth factors and cytokines such as basic fibroblast growth factor, interferon, various enzymes, and transforming growth factor.
• Antioxidant / oxidative-stress pathways: Phlorotannins and meroditerpenoids in the genus are active radical scavengers in vitro.
• Metabolic / glycemic regulation: Enzyme inhibition of α-amylase and α-glucosidase has been proposed on the basis of general Cystoseira genus data.
• Bone health (theoretical): Sulfated polysaccharides of brown seaweed Cystoseira canariensis have been reported to bind to serum myostatin protein; for people with low bone mineral density, natural antagonists of myostatin could theoretically reduce fracture risk during resistance exercise due to decreased exercise intensity. This remains highly speculative and is unsupported by human clinical data.

---

Dosage Forms and Dosages Reported in Studies

The following dosages are drawn exclusively from published peer-reviewed sources and are presented as reported, not as recommendations:

• Human RCT (Willoughby, 2004): The supplemented (MYO) group ingested 1,200 mg/d of Cystoseira canariensis. This was administered over a 12-week period in conjunction with resistance training three times per week.
• Animal study (Bertoncello et al., 2015): Each rat in the supplement groups received 20 mg of the myostatin inhibitor per day. This dose was used in female Wistar rats for eight weeks.
• Commonly cited supplement dose (EBSCO Research Starters): A typical dose of Cystoseira canariensis as a supplement is reported as 1,200 milligrams (mg) per day, often divided into three doses.

No dose-ranging studies, pharmacokinetic studies, or systematic dose-finding trials for C. canariensis in humans were identified in the literature reviewed.

---

Safety Considerations

General Safety Profile

Cystoseira canariensis is thought to be a safe, food-like substance; no serious adverse effects were seen in the human study described above; however, comprehensive safety testing has not been performed.

Absence of Toxicological Data

Comprehensive safety testing has not been performed; maximum safe doses in pregnant or nursing women, young children, and people with liver or kidney disease have not been determined. The available human safety data is limited to the single published 12-week RCT involving 22 untrained males, which is insufficient to characterize the full safety profile of the ingredient.

Iodine Content Considerations

Brown seaweeds including Cystoseira species are known to contain iodine. Excessive consumption of iodine-rich seaweeds can potentially affect thyroid function, an issue documented for several brown algae genera. No specific iodine quantification data for C. canariensis supplements were identified in the peer-reviewed literature consulted.

Heavy Metal Accumulation

Brown macroalgae in coastal environments are known to bioaccumulate heavy metals from surrounding seawater. No peer-reviewed data specifically characterizing heavy metal content in C. canariensis were identified in the literature consulted for this article.

Standardization and Identity Concerns

The accuracy of taxonomic identification of biomass used for the isolation and identification of natural compounds is an important issue concerning the reproducibility and reliability of results, as well as for the implementation of conservation measures for target macroalgae. Given the frequent conflicts between classification of specimens based on morphology and molecular data, there is an inherent uncertainty as to whether commercial preparations labeled as C. canariensis consistently contain material from that specific taxon or from related species.

Drug Interactions

No peer-reviewed studies specifically addressing drug interactions with C. canariensis preparations were identified. As a class, sulfated polysaccharides (including fucoidans) from brown algae have shown anticoagulant properties in vitro in other species; however, this has not been demonstrated specifically for C. canariensis in human studies. No interaction data are available from the sources reviewed.

Ecological and Conservation Context

In the Mediterranean Sea, Cystoseira sensu lato—encompassing the genera Cystoseira sensu stricto, Ericaria, and Gongolaria—is the most diverse group, and many species have been shown to be locally extinct in many areas, resulting in a shift toward structurally less complex habitats with the consequent loss of ecosystem functions and services. This ecological vulnerability is a relevant context for any large-scale commercial harvest of these organisms.

---

Summary Assessment of the Evidence Base

The scientific literature on Cystoseira canariensis as a dietary supplement is narrow and predominantly negative with respect to its most prominent claimed application—myostatin inhibition and skeletal muscle enhancement. The foundational 2003 in vitro study (Ramazanov et al.) demonstrated binding of the species' sulfated polysaccharides to serum myostatin, but this biochemical observation was not replicated in a clinically meaningful outcome in the only published human RCT (Willoughby, 2004), which found no differences between supplemented and placebo groups on any primary or secondary endpoint after 12 weeks of heavy resistance training.

In addition to pharmacological agents, some supplements and nutraceutical agents have demonstrated modulatory effects on myostatin levels; however, the clinical magnitude must be appraised with skepticism before translating mechanistic effects into muscle hypertrophy outcomes.

Broader biological activities—antioxidant, anti-inflammatory, antidiabetic—have been explored in preclinical models using related species in the Cystoseira genus, but these findings cannot be attributed directly to C. canariensis without species-specific human data. The chemical and biological characteristics of Cystoseira species vary significantly depending on species identity, geographic origin, and extraction methodology. The accuracy of taxonomic identification of the biomass used for the isolation and identification of natural compounds is an important issue concerning the reproducibility and reliability of the results.

---

References

• Willoughby DS. Effects of an alleged myostatin-binding supplement and heavy resistance training on serum myostatin, muscle strength and mass, and body composition. Int J Sport Nutr Exerc Metab. 2004;14(4):461–472. PubMed PMID: 15467103.
• Ramazanov Z, Jiménez del Río M, Ziegenfuss T. Sulfated polysaccharides of brown seaweed Cystoseira canariensis bind to serum myostatin protein. Acta Physiol Pharmacol Bulg. 2003;27(2–3):101–106. PubMed PMID: 14570155.
• Ramazanov Z, Jiménez del Río M, Ziegenfuss T. Sulfated polysaccharides of brown seaweed Cystoseira canariensis bind to serum myostatin protein. Semantic Scholar record.
• Willoughby DS, et al. Effects of methoxyisoflavone, ecdysterone, and sulfo-polysaccharide supplementation on training adaptations in resistance-trained males. J Int Soc Sports Nutr. 2007;4:11. PMC2129166.
• Silberfeld T, et al. Improved phylogeny of brown algae Cystoseira (Fucales) from the Atlantic-Mediterranean region based on mitochondrial sequences. PLOS ONE. 2019. PMC6364706.
• Bruno de Sousa C, et al. Cystoseira algae (Fucaceae): update on their chemical entities and biological activities. Tetrahedron: Asymmetry. 2017;28(11):1486–1505.
• AlgaeBase: Cystoseira canariensis Sauvageau. World-wide electronic publication, National University of Ireland, Galway.
• Amira S, et al. Physico-chemical characterization and pharmacological evaluation of sulfated polysaccharides from three species of Mediterranean brown algae of the genus Cystoseira. Daru. 2015;23(1):5. PMC4298055.
• Georgieva D, et al. Structural characterization and in vivo anti-inflammatory activity of fucoidan from Cystoseira crinita (Desf.) Borry. Mar Drugs. 2022;20(11):714. PMC9693085.
• Georgieva D, et al. Fucoidan from Ericaria crinita alleviates inflammation in rat paw edema, downregulates pro-inflammatory cytokine levels, and shows antioxidant activity. Mar Drugs. 2023;21(9):499. PMC10526391.
• Mancini I, et al. The remarkable antioxidant and anti-inflammatory potential of the extracts of the brown alga Cystoseira amentacea var. stricta. Molecules. 2021;26(3):583. PMC7823636.
• Moujaber O, et al. Can macroalgae provide promising anti-tumoral compounds? A closer look at Cystoseira tamariscifolia as a source for antioxidant and anti-hepatocarcinoma compounds. PeerJ. 2016;4:e1704. PMC4768693.
• Aly SH, et al. Phytochemical investigation of three Cystoseira species and their larvicidal activity supported with in silico studies. Mar Drugs. 2023;21(2):117. PMC9967941.
• Santos HO, Cerqueira HS, Tinsley GM. The effects of dietary supplements, nutraceutical agents, and physical exercise on myostatin levels: hope or hype? Nutrients. 2022;14(22):4865. PMC9695935.
• Bertoncello et al. Supplement with Cystoseira canariensis promotes an increase of resistance to the maximum load in the gastrocnemius muscle of female rats. ResearchGate record, 2015.
• EBSCO Research Starters: Cystoseira canariensis's therapeutic uses. Health and Medicine.
• Orellana S, et al. Diversity of Cystoseira sensu lato (Fucales, Phaeophyceae) in the eastern Atlantic and Mediterranean based on morphological and DNA evidence, including Carpodesmia gen. emend. and Treptacantha gen. emend. Eur J Phycol. 2019;54(4):447–465.
• Martínez-Mota P, et al. Cystoseira usneoides: a brown alga rich in antioxidant and anti-inflammatory meroditerpenoids. J Nat Prod. 2016;79(4):1113–1121.